InvestorsHub Logo
Followers 260
Posts 18186
Boards Moderated 0
Alias Born 01/19/2006

Re: None

Tuesday, 09/20/2016 10:28:28 PM

Tuesday, September 20, 2016 10:28:28 PM

Post# of 1850
http://ih.advfn.com/p.php?pid=nmona&article=71789942

Principal subject of PR is very early pre-clinical work of PSTI in connection with use of its PLX-PAD cells to treat DMD.


".......Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration......."
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.